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ABSTRACT 
Objective: The objective of the present investigation was to fabricate and characterize allopurinol loaded chitosan nanoparticles (A-CNPs) for 
sustained release of drug. 
Methods: The allopurinol loaded chitosan nanoparticles were successfully prepared by employing the ionotropic gelation method. Further, particle size 
(PS), polydispersity index (PDI), zeta potential (ZP), Differential Scanning Calorimetry (DSC), entrapment efficiency (EE), Transmission Electron 
Microscopy (TEM), in vitro drug release, X-Ray Diffraction (XRD) and Fourier transform infrared (FTIR) were used for evaluating formulated A-CNPs 
Results: A-CNPs was successfully prepared and the particle size, polydispersity index, ZP and entrapment efficiency were found to be 375.3±10.1 
nm, 0.362±0.01 and 32.5±2.7 mV and 52.56±0.10% respectively. In vitro release profile of A-CNPs showed sustained release and Higuchi model was 
found to be best fit for drug release kinetics. FTIR study depicted no chemical interaction between pure drug allopurinol (AL) and other excipients. 
Conclusion: The sustained release formulation of allopurinol was successfully prepared using HMW chitosan and evaluated for different parameters. 
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Allopurinol (4 hydroxy pyrazolo (3, 4-d) pyrimidine), is a 
hypoxanthine isomer. Allopurinol (AL) acts by competitively inhibiting 
the enzyme xanthine oxidase (XOA), which is responsible for 
catalyzing the oxidation of normal purines to uric acid (UA) [1]. 
Allopurinol is a UA lowering therapeutic agent mainly used for the 
treatment of hyperuricemia and its related complications such as UA 
nephrolithiasis, hyperuricosuric, gout, urate nephropathy etc. [2, 3]. 
Allopurinol is very slightly soluble in water, possesses a short half-life 
of 1-2 h and its oral dose is 100-300 mg (once a day). The poor 
solubility and shorter half-life leads to lesser bioavailability of drug via 
the oral route and this strongly indicates the urge for the development 
of sustained release formulation of allopurinol for enhancing 
bioavailability [4]. Colloidal drug carriers such as nanoparticles have 
attained a potential place in the controlled drug delivery systems. 
Nanoparticles are solid polymeric colloidal particles, in which the 
therapeutic agent is either encapsulated, entrapped or adsorbed onto 
the surface. They are prepared from natural (chitosan, alginate, gelatin 
etc.) or artificial (polylactides, polymethacrylate etc.) polymers and 
their size ranges from 10-1000 nm [5-7]. Various factors have to be 
considered while selecting a polymer for developing polymeric 
nanoparticles such as desired nano-particle size and drug release 
profile, biocompatibility, toxicity, biodegradability, drug inherent 
property and surface characteristics. Chitosan is a naturally occurring 
polysaccharide, obtained after deacetylation of chitin and it is studied 
extensively for the development of polymeric nanoparticles. Chitosan 
has various traits like chemical versatility, biocompatibility, 
biodegradability, non-toxic, cost effectiveness etc, which makes it an 
appropriate choice as a drug delivery carrier [8]. In the present 
investigation, sustained release allopurinol loaded chitosan 
nanoparticles (A-CNPs) were prepared by ionotropic gelation method 
where chitosan was crosslinked to tripolyphosphate (TPP) molecules 
that will protect the drug from harsh gastrointestinal environment and 
improves drug bioavailability and solubility by nanonization. The 
formulated A-CNPs was also evaluated for different parameters such 
as PS, entrapment efficiency, in vitro drug release, FTIR study etc. 
MATERIALS AND METHODS 
Materials 
Allopurinol (AL) was received as a gift sample from Indoco 
Remedies Ltd. Maharashtra, India. High molecular weight (HMW) 
chitosan (CS) and sodium tripolyphosphate (TPP) was obtained 
from SRL Pvt Ltd, Mumbai, India. Acetic acid glacial (99.8%) was 
sourced from Thomas Baker Chemicals, India. All other reagents 
used in this research work were of analytical grade. 
Preparation of Allopurinol loaded chitosan nanoparticles (A-
CNPs) 
A-CNPs were fabricated by employing the modified ionotropic geltation 
method [9]. CS solution (0.2% w/v) was prepared by dissolving HMW CS 
in 2% glacial acetic acid under continuous stirring and pH adjustment to 
5.6 was made by adding sodium hydroxide solution. Subsequently, 100 
mg of allopurinol was added to the freshly prepared CS solution and 
stirred for 30 min. Further, an aqueous solution of crosslinker TPP was 
prepared in deionized water for obtaining a TPP: chitosan ratio of 1:3. 
TPP solution was then injected dropwise to the above solution and kept 
on 1 h stirring (1000 rpm) to allow electrostatic interactions among two 
oppositely charged moieties for the formation of A-CNPs. The dispersion 
was then, centrifuged at 15000 rpm (4°C, 30 min) for isolating 
nanoparticles as pellet and the supernatant was collected for further 
analysis. The pellet was washed, re-dispersed in deionized water (10 ml) 
and again centrifuged at 15000 rpm (4°C, 30 min) to obtain 
nanoparticles in the pellet form. The pellet was redispersed in 10 ml 
deionized water and this dispersion was later utilized for evaluating 
various parameters. The A-CNPs dispersion was finally freeze-dried by 
employing lyophilizer.  
Entrapment efficiency  
The supernatant collected after centrifugation of A-CNPs dispersion was 
analyzed in triplicate for estimating the amount of free drug. The 
absorbance of the supernatant sample was measured by using UV 
spectrophotometer at λ max 250 nm against suitable blank. Entrapment 
efficiency was calculated by using the equation mentioned below [10]:  
Drug content estimation =
Total AL content − free AL content
Total AL content
 ∗ 100 
PS, PDI and ZP 
Suitable dilution of A-CNPs dispersion (10 times) was prepared for 
estimating the particle size (PS), polydispersity index (PDI) and zeta 
potential (ZP) in triplicate on Zetasizer (Malvern Instruments, U. K.) 
by using dynamic light scattering technique. The scattering was 
recorded at 90 ° angle and 25 °C temperature [11, 12]. 
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Transmission electron microscopy 
TEM was performed for examining the surface morphology and PS 
of formulated A-CNPs by using High-resolution transmission 
electron microscope (TECNAI, at 200 kV). Sample for TEM analysis 
was prepared by suitably diluting the A-CNPs with HPLC grade 
water and further sonicated for ensuring particle deaggregation. A 
drop of dispersion was put on a copper grid coated with carbon film 
(300 mesh) and stained (2% phosphotungstic acid, pH 7) before 
recording TEM images [13, 14].  
In vitro drug release 
The release profile of AL from A-CNPs was evaluated through 
dialysis technique on a USP paddle (Type 2) dissolution apparatus. 
The dissolution medium (500 ml) consisted of phosphate buffer (pH 
7.4, 37 °C±0.5 °C) with paddle rotating speed of 100 rpm. A-CNPs 
(equivalent to 4 mg AL, redispersed in 3 ml phosphate buffer) was 
introduced inside the dialysis bag which was previously soaked for 1 
h in distilled water before the experiment and the bag was safely 
closed from both ends. The dialysis bag was then immersed in 
dissolution medium and 5 ml sample aliquots were withdrawn at 
regular intervals of time from dissolution media and were replaced 
with an equal amount of fresh buffer solution for maintaining sink 
conditions. The aliquots were then analyzed (triplicate) 
spectrophotometrically at λmax =250 nm for determining percent 
drug release. The data procured from the in vitro study of A-CNPs 
was further evaluated for different drug release kinetic models 
(Higuchi, Korsemeyer Peppas, Hixson-Crowell, zero order, and first 
order) [15, 16]. 
Fourier-transform infrared spectroscopy 
FTIR spectrum of pure AL, HMW CS, dummy chitosan nanoparticles 
(CNPs) i. e without drug and lyophilized allopurinol loaded chitosan 
nanoparticles (A-CNPs) were observed on FTIR spectrophotometer 
(4000-400 cm-1
X-ray diffraction  
) by using KBr method. FTIR spectroscopy was 
carried out for investigating any kind of chemical interactions 
among pure AL and other excipients in A-CNPs formulation [17]. 
X-ray diffractograms of pure AL and lyophilized A-CNPs were 
procured on X-ray diffractometer (Rigaku MiniFlex II) for examining 
the physical state of pure drug (AL) and its interaction with other 
carriers in the formulation. The source of X-ray was CopperKα 
(λ=1.5405 °A) monochromatic radiation, operated at 30kV and 
15mA. The samples were scanned between 2 theta range of 10 °-80 
°, with an increment in a step size of 0.02° and time of 2 s [18]. 
Differential scanning calorimetry  
DSC thermograms of AL, lyophilized A-CNPs, CNPs and physical 
mixture of AL and HMW chitosan (P-AC) were acquired on DSC 
equipment (TA Instruments, Q-10, USA), which was operated in the 
temperature range of 25 ° to 400 °C under nitrogen inert 
environment with heat flowing at 10 °C/min. DSC analysis was 
performed for investigating the polymorphic changes in drug state 
in formulation [19]. 
RESULTS AND DISCUSSION 
Entrapment efficiency (EE) 
The percent EE of A-CNPs was determined by employing the 
abovementioned method and it was found to be 52.56±0.10 % 
(mean±SD, n = 3). 
PS, PDI and ZP 
The mean PS (hydrodynamic diameter), PDI and ZP of A-CNPs were 
observed to be 375.3±10.1 nm, 0.362±0.01 and 32.5±2.7 mV 
respectively (n = 3). The formulated A-CNPs was found to be in nano 
range and low value of polydispersity index signifies the formulation 
to be stable and monodisperse in nature. Further, high positive ZP of 
A-CNPs suggest greater electrostatic repulsion between particles in 
dispersion and thus making it more stable by preventing 
aggregation [13]. 
Transmission electron microscopy 
The TEM micrograph of A-CNPs has been displayed in fig. 1, which 
indicates that the particles were present as discrete units and having a 
spherical shape. The PS of A-CNPs as obtained by TEM technique was 
in the range of 230-290 nm, which was lesser than that procured by 
zetasizer. This may have occurred due to the dehydration of A-CNPs 
while preparing its sample for TEM analysis [9].  
 
 
Fig. 1: TEM micrograph of A-CNPs 
 
In vitro drug release  
Fig. 2, depicts the sustained release pattern of allopurinol from A-CNPs 
and it showed % cumulative release of 51.58±0.86 % (n=3) in 6 h. The 
data acquired from in vitro study of A-CNPs was further analysed with 
different kinetic models (Higuchi, Hixson–Crowell, Korsemeyer–
Peppas, first order and zero model). The maximum linearity with 
correlation coefficient (R2
 
) of 0.9916 was obtained for Higuchi model, 
signifying drug release from A-CNPs was mainly controlled by 
diffusion process and the value of release component (n) was found to 
be 0.59 which lies in the range of 0.45 and 0.89, depicting that the drug 
release follows non Fickian transport mechanism [15].  
 
Fig. 2: In vitro drug release profile of A-CNPs, mean±SD, n = 3 
 
Fourier-transform infrared spectroscopy 
FTIR spectrum of AL, HMW CS, CNPs and lyophilized A-CNPs are 
shown in fig. 3. The principal peaks at 3360, 3043, 1705, 1764 and 
1593 cm−1 were obtained in the spectrum of AL [20]. The spectra of 
HMW chitosan showed a broad band at 3416 cm−1(OH) and sharp 
peaks at 2956 cm−1 (CH) and 1654 cm−1 (NH). In the CNPs, the 1654 
cm−1peak of NH bending disappears and a new peak at 1643 
cm−1appears, which can be ascribed to the linkage between 
tripolyphosphate and ammonium group of TPP and chitosan, 
respectively. Also, a new peak at 1224 cm−1 (PO stretching) 
appeared in the CNPs which was not present in the spectra of pure 
HMW chitosan [21]. All the principal peaks of pure drug AL were 
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present in FTIR spectra of lyophilized A-CNPs, thus indicating no 
chemical interaction between pure AL and other excipients. 
 
 
Fig. 3: FTIR spectra of pure drug AL, A-CNPs, CNPs, and HMW 
chitosan 
 
Differential scanning calorimetry  
DSC thermograms of AL, A-CNPs, CNPs, and P-AC have been shown in fig. 
4. A sharp endothermic peak at 383 °C was obtained in the DSC curve of 
AL, demonstrating its crystallinity and melting point. There was no 
chemical interaction seen between pure AL and HMW chitosan in the 
DSC curve of P-AC, as the characteristic endothermic peak of AL (383 °C) 
and HMW chitosan (101 °C) appeared separately in the graph. In 
addition, the thermogram of P-AC showed an exothermic peak around 
310 °C which corresponds to the degradation of amine unit of chitosan 
and this peak disappeared in the thermograms of CNPs and A-CNPs. 
Instead, a new prominent exothermic peak around 249 °C was observed 
in thermogram of CNPs and A-CNPs. This is possibly due to the breakage 
of the electrostatic bond between polyanionic TPP and polycationic 
chitosan. Further, in the DSC thermogram of A-CNPs, no endothermic 
peak for AL was appeared around 383 °C, which signifies that the AL 
drug had been incorporated into the chitosan matrix in an amorphous 
state. These results are further confirmed with XRD analysis [22]. 
 
 
Fig. 4: DSC thermograms of pure drug AL, P-AC, A-CNPs and CNPs 
 
X-ray diffraction  
The physical state of AL and A-CNPs was examined by XRD analysis. 
The diffractograms of allopurinol and A-CNPs are shown in fig. 5 
which demonstrates the high-intensity diffraction peaks for pure 
allopurinol drug (2θ = 14.61°, 17.35°, 25.80°, 27.68°), depicting its 
crystalline nature. However, the intensity of diffraction peaks of 
pure AL was reduced in A-CNPs formulation, confirming its 
successful encapsulation in the A-CNPs and its transformation from 
less soluble crystalline form to more soluble amorphous form [23].  
 
 
Fig. 5: XRD pattern of pure drug AL and A-CNPs 
 
CONCLUSION 
The present research work describes successful development of 
sustained release nanoparticlulate formulation of AL by its 
incorporation into chitosan-TPP matrix. The particle size of 
prepared A-CNPs lied in the nano range and they showed a 
sustained release pattern. Polydispersity index and ZP values 
depicts the formulation to be stable. DSC and XRD studies affirms the 
transformation of physical state of AL in formulation to amorphous 
state (more soluble form). Further, in vivo studies can improve their 
potential role in drug targeting and for the benefit of mankind.  
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